- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
A.L.I. acquisition reaches completion
McKesson announced July 8 the final acquisition of A.L.I. Technologies. The A.L.I. line of PACS products, now known as Horizon Medical Imaging, complements McKesson's Horizon Clinicals suite. Together, the two technologies will provide integrated access
McKesson announced July 8 the final acquisition of A.L.I. Technologies. The A.L.I. line of PACS products, now known as Horizon Medical Imaging, complements McKesson's Horizon Clinicals suite. Together, the two technologies will provide integrated access to the complete patient record. The goal behind the acquisition is to consolidate the technologies needed to automate and streamline workflow along every step of the diagnostic process from the time a test is ordered until the image is interpreted and the results are distributed to the referring physician, according to the company. The acquisition boosts McKesson's customer base to more than 500 installations. A.L.I. will be known as the McKesson Medical Imaging Group. Its employees will remain in the Vancouver, BC, location.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
